Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03891953 | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | PHASE1 | ACTIVE NOT_RECRUITING | 98 | — | — | May 7, 2019 | Oct 31, 2026 | Jan 21, 2026 | 9 | United States, Germany +4 |
Incidence and severity of AEs and SAEs
The incidence of DLTs during the first cycle of treatment with single agent DKY709 or the combination of DKY709 with PDR001.
Incidence and severity of AEs and SAEs
| Arm | Type | Description |
|---|---|---|
| DKY709 | EXPERIMENTAL | DKY709 monotherapy |
| DKY709 + PDR001 | EXPERIMENTAL | Combination therapy with DKY709 and PDR001 |
| Name | Type | Description |
|---|---|---|
| DKY709 | DRUG | Novel immunomodulatory agent |
| PDR001 | DRUG | PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2 |
Inclusion Criteria: 1. Signed informed consent must be obtained prior to participation in the study. 2. Patients must be ≥18 years of age at the time of informed consent form (ICF) signature. 3. Patients with advanced/metastatic cancer who have progressed despite having received standard therapy in...